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Abstract
Background: Patients with complicated urinary tract infections (cUTIs) frequently receive broad-spectrum antibiotics.
We aimed to determine the prevalence and predictive factors of multidrug-resistant gram-negative bacteria in patients
with cUTI.
Methods: This is a multicenter, retrospective cohort study in south and eastern Europe, Turkey and Israel including
consecutive patients with cUTIs hospitalised between January 2013 and December 2014. Multidrug-resistance was
defined as non-susceptibility to at least one agent in three or more antimicrobial categories. A mixed-effects logistic
regression model was used to determine predictive factors of multidrug-resistant gram-negative bacteria cUTI.
Results: From 948 patients and 1074 microbiological isolates, Escherichia coli was the most frequent microorganism
(559/1074), showing a 14.5% multidrug-resistance rate. Klebsiella pneumoniae was second (168/1074) and exhibited
the highest multidrug-resistance rate (54.2%), followed by Pseudomonas aeruginosa (97/1074) with a 38.1% multidrug-
resistance rate. Predictors of multidrug-resistant gram-negative bacteria were male gender (odds ratio [OR], 1.66; 95%
confidence interval [CI], 1.20–2.29), acquisition of cUTI in a medical care facility (OR, 2.59; 95%CI, 1.80–3.71), presence
of indwelling urinary catheter (OR, 1.44; 95%CI, 0.99–2.10), having had urinary tract infection within the previous year
(OR, 1.89; 95%CI, 1.28–2.79) and antibiotic treatment within the previous 30 days (OR, 1.68; 95%CI, 1.13–2.50).
Conclusions: The current high rate of multidrug-resistant gram-negative bacteria infections among hospitalised
patients with cUTIs in the studied area is alarming. Our predictive model could be useful to avoid inappropriate
antibiotic treatment and implement antibiotic stewardship policies that enhance the use of carbapenem-sparing
regimens in patients at low risk of multidrug-resistance.
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Background
Urinary tract infections (UTIs) are one of the most com-
mon bacterial infections [1]. Complicated urinary tract
infections (cUTIs), occurring in individuals with functional
or structural urinary tract abnormalities, are a leading cause
of hospital admissions, hospital-acquired infections, and
antibiotic use [2].
The prevalence of cUTIs is difficult to assess accur-
ately. Data from the most recent point prevalence survey
of healthcare-associated infections (HAIs) in European
acute care hospitals showed that UTI was the third most
common cause, accounting for 19% of estimated 3.2
million overall cases of HAIs [3]. This figure, although
huge, clearly underestimates the overall cUTI incidence
in Europe because it did not include patients developing
cUTIs in the community and in long-term care facilities
(LTCFs). In LTCFs, cUTIs occur in more than one mil-
lion patients annually [4]. Aging, comorbidities, and an
increasing number of invasive urologic procedures for
both diagnosis and treatment have been related to this
high prevalence of cUTIs in the European population.
Antibiotic resistance has become a major healthcare
problem in Europe and worldwide [5, 6]. Currently, mul-
tidrug-resistant (MDR) gram-negative bacteria (GNB)
pose a threat in hospitals and nursing homes [7]. Accord-
ing to the recent Annual Report of the European Anti-
microbial Resistance Surveillance Network (EARS-Net)
[8], MDR rates showed large variations across Europe,
being higher in southern and south-eastern Europe than
in northern Europe. Patients with suspected cUTIs are
frequently treated empirically with broad-spectrum antibi-
otics. Developing a model that helps select patients at high
risk for MDR could be useful when choosing empirical
antibiotic regimens and in antibiotic stewardship policies.
Considering the lack of contemporary data on hospita-
lised patients with cUTIs, we aimed to determine the
prevalence of MDR among hospitalised patients with cUTIs
in countries with high MDR-GNB prevalence and develop
a predictive model to determine the risk of MDR-GNB in-
fections, which would be useful to select more targeted




The COMBACTE-MAGNET, WP5 RESCUING Study was
a multicenter, retrospective, observational cohort study in-
cluding hospitalised patients with cUTI from January 2013
to December 2014. Data was collected from patients
who were diagnosed with cUTI as the primary cause of
hospitalisation and from patients who were hospitalised
for other reasons but who developed cUTIs during their
hospitalization [9]. This study conformed to the STROBE
guidelines for reporting observational studies [10].
Setting and patients
The study was conducted in Bulgaria (2 hospitals), Greece
(2 hospitals), Hungary (3 hospitals), Israel (3 hospitals), Italy
(3 hospitals), Romania (2 hospitals), Spain (3 hospitals) and
Turkey (2 hospitals). Patients were identified by searching
for the appropriate International Classification of Diseases
(ICD)-9 Clinical Modification (CM) or ICD-10 CM Codes
[11, 12] at discharge from hospital (diagnoses are detailed
in Additional file 1). All patients who met the criteria for
cUTI were selected for data collection. In order to avoid se-
lection bias, each hospital included 50 to 60 consecutive pa-
tients with cUTI until achieving the total estimated sample
size of 1000 patients.
Complicated urinary tract infection inclusion criteria
followed the Food and Drug Administration (FDA) guid-
ance on cUTI [13], and consisted on:
 Patients with UTI and at least one of the following
underlying conditions: a) indwelling urinary catheter;
b) urinary retention (at least 100 mL of residual urine
after voiding); c) neurogenic bladder; d) obstructive
uropathy (e.g., nephrolithiasis, fibrosis); e) renal
impairment caused by intrinsic renal disease
(estimated glomerular filtration rate < 60 mL/min); f )
renal transplantation; g) urinary tract modifications,
such as an ileal loop or pouch; or h) pyelonephritis.
 And at least one of the following signs or symptoms: a)
chills or rigors associated with fever or hypothermia
(temperature > 38 °C or < 36 °C); b) flank pain
(pyelonephritis) or pelvic pain (cUTI); c) dysuria, urinary
frequency, or urinary urgency; or d) costovertebral angle
tenderness on physical examination.
 And urine culture with ≥105 colony-forming units/
mL of uropathogen (no more than two species) or;
 At least one blood culture growing possible
uropathogens (no more than two species) with no
other evident site of infection.
The exclusion criteria were as follows: a) patients
aged < 18 years, b) diagnosis of prostatitis according to
FDA guidance, c) polymicrobial infections including
Candida spp., d) polymicrobial infections including more
than two bacterial species, or e) cUTI with Candida spp. as
sole uropathogen, d) patients with uncomplicated cystitis.
If a patient had more than one episode of cUTI during
the same hospitalisation, only the first episode was included.
Data collection and validation
Data on demographic characteristics, comorbidities, place
of acquisition of infection, signs and symptoms of infection,
laboratory and microbiology, imaging tests, management of
infection including antibiotic therapy and interventional
procedures, details of discharge and outcome of infec-
tion, including death if applicable, were reviewed by
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professionals who received web-database training sessions.
For data collection, an access-controlled web-based elec-
tronic case report form was used. At each site, a screening
log was kept of the patients with infections detected ac-
cording to the ICD codes, detailing the excluded patients
and the reasons for exclusion. To confirm data quality,
study sites were monitored and audited by a contract re-
search organization (CRO) from Utrecht, Netherlands.
Definitions
Acquisition of cUTI in a medical care facility was con-
sidered if it was:
 Hospital-acquired: if it started ≥48 h after hospital
admission.
 Healthcare-associated: if it was detected at hospital
admission or within the first 48 h of hospitalization,
with the patient fulfilling any of the following criteria:
1) receiving intravenous therapy, wound care, or
specialized nursing care at home in the previous
30 days; 2) admission in the hospital or haemodialysis
ward or receiving intravenous chemotherapy in the
previous 30 days; 3) hospitalization for ≥2 days in the
previous 90 days; 4) residence in a long-term care
facility; 5) underwent invasive urinary procedure
within the previous 30 days; or 6) having a long-term
indwelling urinary catheter.
We used the following categories for cUTIs:
 UTI related to indwelling urinary catheterization,
including long-term, short-term, or intermittent
catheterization
 Pyelonephritis with no other urinary tract
modification, defined as sepsis, flank pain or
costovertebral angle tenderness
 UTI related to anatomical urinary tract modification,
including any urinary diversion procedure,
nephrostomy or stents, or renal transplants
 UTI related to obstructive uropathy, including any
obstruction intrinsic or extrinsic to the urinary tract,
such as lithiasis, tumor, ureteral herniation, or
prostate hyperplasia
 UTI related to other events that do not fall under
any other category
Multidrug resistance was defined according to an
international expert proposal by Magiorakos et al. [14], as
non-susceptibility to at least one agent in three or more
antimicrobial categories (extended-spectrum penicillins,
carbapenems, cephalosporins, aminoglycosides, and fluoro-
quinolones). Extensively drug-resistance (XDR) was defined
as non-susceptibility to at least one agent in all but
two or fewer antimicrobial categories (i.e., bacterial isolates
remaining susceptible to only one or two categories) tested
for a determined microorganism.
Outcomes
The primary outcome was the presence of MDR, as
previously defined.
Secondary outcomes included the following:
 Estimation of the MDR prevalence in each country
and participating hospital
 Definition of the most prevalent microbiology
according to source of infection
 Assessment of the resistance rate of the main GNB
to the different antimicrobial classes
Statistical methods
The chi-square or Fisher’s exact test was used to compare
categorical data, and Student’s t-test or the Mann-Whitney
U test to compare continuous data, as appropriate. The
quantile-quantile normality plot and Kolmogorov-Smirnov
test were used to assess whether a continuous variable was
normally distributed.
Predictive model of MDR in patients with cUTI
Countries and hospitals presented a non-homogeneous
MDR baseline risk. To account for such variations, a
mixed-effects logistic regression model to predict the risk
of MDR in patients with cUTIs, including all different epi-
demiological and clinical variables, was built using hospi-
tals as clusters. First, a stepwise selection method based
on the Akaike Information Criterion was performed to iden-
tify variables that explained the bulk of MDR infections. Ad-
equacy of the final model was assessed by collinearity,
influential observations, and residuals. To evaluate discrimin-
ation properties, the Hosmer-Lemeshow goodness-of-fit test
was used. Moreover, the bootstrapping resampling method
was used to improve the robustness of estimated standard
errors. Results were given as odds ratios (OR) and 95% confi-
dence intervals (95% CI). All tests were two-tailed, and a
p-value of < 0.05 was considered statistically significant.
All data were analyzed using R software (2017). R
Foundation for Statistical Computing, Vienna, Austria.
Results
Patients’ epidemiological characteristics and univariate
analysis of MDR-GNB
Fifty-two cases were excluded due to lack of information
on the presence of MDR, leaving a final sample of 948 pa-
tients. Among them, 1074 bacterial isolates were obtained.
The patients’ clinical characteristics are shown in Table 1.
Females comprised 56%, the mean age was 65.8 ± 18.2 years,
34.4% were admitted due to conditions other than cUTIs,
17.4% came from LTCFs, and 46% were functionally
dependent. Factors associated with MDR by univariate
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Male gender, n (%) 420 (44.3) 270 (39.1) 150 (58.4) < 0.001
Mean age (SD), years 65.8 (18.2) 65.6 (18.6) 66.5 (16.8) 0.526
Elective admission, n (%) 141 (14.9) 97 (14) 44 (17.1) 0.236
Admission reason: conditions other than cUTI, n (%) 326 (34.4) 214 (31) 112 (43.6) < 0.001
Place of residency: long-term care facility, n (%) 165 (17.4) 98 (14.2) 67 (26.1) < 0.001
Underlying disease, n (%)
Acute myocardial infarction 79 (8.3) 56 (8.1) 23 (8.9) 0.676
Congestive heart failure 182 (19.2) 134 (19.4) 48 (18.7%) 0.804
Peripheral vascular disease 70 (7.4) 55 (8) 15 (5.8) 0.267
Cerebrovascular disease 182 (19.2) 122 (17.7) 60 (23.3) 0.048
Dementia 130 (13.7) 93 (13.5) 37 (14.4) 0.709
Chronic pulmonary disease 135 (14.2) 91 (13.2) 44 (17.1) 0.122
Connective tissue disease 21 (2.2) 15 (2.2) 6 (2.3) 0.879
Peptic ulcer 46 (4.9) 34 (4.9) 12 (4.7) 0.873
Diabetes mellitus 250 (26.4) 186 (26.9) 64 (24.9) 0.531
Chronic kidney disease 263 (27.7) 191 (27.6) 72 (28) 0.909
Hemiplegia 86 (9.1) 58 (8.4) 28 (10.9) 0.233
Leukaemia 9 (0.9) 6 (0.9) 3 (1.2) 0.673
Lymphoma 13 (1.4) 11 (1.6) 2 (0.8) 0.338
Chronic liver disease 50 (5.3) 35 (5.1) 15 (5.8) 0.637
Solid tumour 114 (12.3) 75 (11.1) 39 (15.4) 0.075
Metastatic tumour 47 (5) 35 (5.1) 12 (4.7) 0.803
Valvulopathy 88 (9.3) 69 (10) 19 (7.4) 0.221
HIV infection 10 (1.1) 8 (1.2) 2 (0.8) 0.611
Charlson index ≥ 3, n (%) 418 (44.1) 299 (43.3) 119 (46.3) 0.403
Organ transplant, n (%) 65 (6.9) 45 (6.5) 20 (7.8) 0.492
Immunosuppression, n (%) 94 (9.9) 64 (9.3) 30 (11.7) 0.270
Steroids, n (%) 68 (7.2) 46 (6.7) 22 (8.6) 0.313
Functional capacity: dependent, n (%) 436 (46.1) 298 (43.3%) 138 (53.9) 0.003
Prior UTI (within the previous year), n (%) 247 (26.1) 167 (24.2) 80 (31.2) 0.027
Prior antibiotics (within the previous 30 days), n (%) 190 (20.1) 120 (17.4) 70 (27.6) 0.001
Prior quinolone 64 (6.8) 38 (5.5) 26 (10.2) 0.010
Prior Penicillin 55 (5.8) 35 (5.1) 20 (7.9) 0.103
Prior cephalosporin 42 (4.4) 27 (3.9) 15 (5.9) 0.188
Prior Carbapenem 22 (2.3) 10 (1.4) 12 (4.7) 0.003
Prior other antibiotics 51 (5.4) 31 (4.5) 20 (7.9) 0.042
Acquisition in a medical care facility, n (%) 410 (43.2) 244 (35.3) 166 (64.6) < 0.001
Source of cUTI, n (%)
Indwelling urinary catheterisation 308 (32.5) 189 (27.4) 119 (46.3) < 0.001
Pyelonephritis with normal tract anatomy 196 (20.7) 164 (23.7) 32 (12.5) < 0.001
Obstructive uropathy 152 (16) 114 (16.5) 38 (14.8) 0.523
Urinary tract diversion 84 (8.9) 64 (9.3) 20 (7.8) 0.476
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analysis were male gender, admission due to reasons other
than cUTIs, residing in LTCF, dependent functional cap-
acity, UTI within the previous year, antibiotic treatment
within the previous 30 days, acquisition of cUTI in a med-
ical care facility, and presence of an indwelling urinary
catheter.
Most frequent bacterial aetiology and patterns of
antimicrobial resistance
Of all bacterial isolates (n = 1074), the most frequent was
Escherichia coli, isolated in 52% of samples, followed by
Klebsiella pneumoniae in 15.6%, Pseudomonas aerugi-
nosa in 9%, Proteus mirabilis in 7.3%, and Enterococcus
spp. in 3.2%. Only these 5 bacteria were evaluated due to
their clinical significance. Escherichia coli was mainly re-
lated to pyelonephritis with normal urinary tract (76.5%),
while K. pneumoniae was more frequently associated with
urinary tract diversion (22.6%). Pseudomonas aeruginosa,
P. mirabilis and Enterococcus spp. were significantly re-
lated to the presence of an indwelling urinary catheter
(18.8%, 25.6% and 5.8% respectively) (Table 2).
Significant differences in MDR rate occurred between
the different participating hospitals, ranging from < 20%
in some countries such as Hungary and Spain to almost
60% in other countries such as Bulgaria and Greece
(Fig. 1a). The MDR rates by hospital varied in accord-
ance with the country’s trend (Fig. 1b).
The antimicrobial resistance patterns according to the
most frequent GNB are shown in Table 3. Escherichia
coli had a fluoroquinolone resistance rate of 39.5%, a
third-generation cephalosporin (3GC) resistance rate of
24.2% and a MDR rate of 14.5%. Klebsiella pneumoniae
exhibited the highest MDR rate (54.2%), followed by P.
aeruginosa (38.5%) and P. mirabilis (24.1%). By anti-
biotic class, fluoroquinolones had the highest resistance
rates (39.5% in E. coli, 56.5% in K. pneumoniae, 42.1% in
P. aeruginosa, and 55.7% in P. mirabilis), followed by
3GC and aminoglycosides (Table 3). Resistance to carba-
penems was 32.6% in P. aeruginosa, 19.6% in K. pneu-
moniae and 2.3% in E. coli.
Predictive model of MDR-GNB in patients with cUTIs
Identified predictive factors for MDR risk are reported
in Table 4. The resulting equation and an illustrative ex-
ample for calculating MDR-GNB risk are described in
Additional file 1. The proposed model had good discrim-
ination for MDR prediction, with a 0.80 statistic (area
under the receiver operating characteristic curve) (Fig. 2).
Calibration was also excellent, with a good observed/ex-
pected ratio of MDR risk by deciles of predicted risk
(Fig. 3a) and by hospital (Fig. 3b).
The factors that best predicted the bulk of MDR pres-
ence were male gender (odds ratio [OR], 1.66; 95% con-
fidence interval [CI], 1.20–2.29), acquisition of cUTI in a
medical care facility (OR, 2.59; 95% CI, 1.80–3.71), pres-
ence of an indwelling urinary catheter (OR, 1.44; 95%
CI, 0.99–2.10), having a UTI within the previous year
(OR, 1.89; 95% CI, 1.28–2.79), and antibiotic treatment
within the previous 30 days (OR, 1.68; 95% CI, 1.13–2.50)
(Table 4).









Other 208 (21.9) 160 (23.2) 48 (18.7) 0.139
Shock/severe sepsis, n (%) 140 (15.9) 104 (16.2) 36 (14.9) 0.635
MDR multidrug resistance, SD standard deviation, cUTI complicated urinary tract infection, HIV human immunodeficiency virus, UTI urinary tract infection
Table 2 Most frequent bacterial aetiology of complicated urinary tract infections according to source of infection
(sources = 948, isolations = 1074)
Source (n = 948) E. coli
n = 559 (52%)
K. pneumoniae
n = 168 (15.6%)
P. aeruginosa
n = 97 (9%)
P. mirabilis
n = 79 (7.3%)
Enterococcus spp.
n = 34 (3.2%)
Indwelling urinary catheterisation
(n = 308), n (%)
124 (40.3%) 63 (20.4%) 58 (18.8%) 40 (25.6%) 18 (5.8%)
Pyelonephritis with normal tract
anatomy (n = 196), n (%)
150 (76.5%) 25 (12.7%) 4 (2.0%) 13 (6.6%) 0 (0.0)
Obstructive uropathy (n = 152), n (%) 98 (64.4%) 26 (17.1%) 12 (7.9%) 11 (7.2%) 5 (3.3%)
Urinary tract diversion (n = 84), n (%) 48 (57.1%) 19 (22.6%) 10 (11.9%) 2 (2.4%) 4 (4.8%)
Others (n = 208), n (%) 139 (66.8%) 35 (16.8%) 13 (6.2%) 13 (6.2%) 7 (3.4%)
E. coli, Escherichia coli; K. pneumoniae, Klebsiella pneumoniae; P. aeruginosa, Pseudomonas aeruginosa; P. mirabilis, Proteus mirabilis; Enterococcus spp., Enterococcus
species. First column include all sources of infection (n = 948), and first raw include the five more frequent bacteria taking as denominator the total number of isolations
(n = 1074). All other isolates up to the total number are not included in the table. Denominators in central boxes are the total number of each row (sources)
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Discussion
This large, multicenter, retrospective cohort study of
hospitalised patients with cUTIs provides a comprehen-
sive update about antibiotic resistance in countries with
high MDR incidence. In this cohort, K. pneumoniae had
the highest MDR rate among all the GNB analysed, and
fluoroquinolones had the highest resistance rates. We de-
veloped a model to predict the risk of cUTIs caused by
MDR organisms, in order to avoid inappropriate treat-
ment and help establish antibiotic stewardship policies.
In our cohort, E. coli continues to be the most frequent
cause of cUTI, as previously observed [15, 16]. Although
it was associated with low MDR levels, it showed a fluoro-
quinolone resistance rate of almost 40% and a 3GC resist-
ance rate of 24%. Previous studies already described an
increased resistance rate of E. coli to fluoroquinolones and
Fig. 1 Cumulative multidrug-resistant gram-negative bacteria incidence with 95% confidence interval by country (a) and by hospital (b). Figure 1
shows the cumulative incidence with 95% confidence interval of multidrug-resistant (MDR) gram-negative bacteria in complicated urinary tract
infection observed in each participating country (a) and in each participating hospital (b). Hosp. Univ. 12 de Octubre: Hospital Universitario 12 de
Octubre, Hosp. Univ. Virgen Macarena: Hospital Universitario Virgen de la Macarena, Hosp. Univ. Bellvitge: Hospital Universitari de Bellvitge
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trimethoprim-sulfamethoxazole, precluding their use as
empiric treatment in mild and severe infections [16, 17].
Similar to our results, the Study for Monitoring Antimicro-
bial Resistance Trends (SMART) in the United States
showed a 35% resistance rate of E. coli to ciprofloxacin [18].
This high fluoroquinolone resistance rate contrasts with
the 20% reported by the EARS-Net in 2016 [8]. However,
the rate was obtained by including northern European
countries that had low antimicrobial resistance rates.
On the contrary, the south-eastern countries showed rates
similar to those observed in our study. Besides, the
EARS-Net included only invasive isolates, a sample profile
quite different to ours. MDR rates similar to our results
were also observed in the Asia-Pacific region [19].
In our cohort, K. pneumoniae was the second most fre-
quent microorganism, showing a remarkably carbapenem-
resistance rate of almost 20% and having ileal loop or
urinary diversion as the most frequent source of infection.
The countries with the highest rate of carbapenem-resistant
K. pneumoniae were Greece and Turkey, while those with
the lowest were Spain and Hungary. This study did not
analyse the type of resistance mechanisms present in
Enterobacteriaceae; nevertheless, phenotypic resistance to
carbapenems commonly results from acquiring carbapene-
mases that affect even the latest generations of penicillins
and cephalosporins, in addition to other antibiotic fam-
ilies such as aminoglycosides and fluoroquinolones.
The European survey of carbapenemase-producing En-
terobacteriaceae (EuSCAPE), performed in 2013–2014 in
Europe, Turkey, and Israel, showed that K. pneumoniae and

















108 (19.3) 221 (39.5) 135 (24.2) 57 (10.2) 13 (2.3) 81 (14.5) 2 (0.4)
K. pneumoniae
(n = 168)
77 (45.8) 95 (56.5) 98 (58.3) 64 (38.1) 33 (19.6) 91 (54.2) 23 (13.7)
P. aeruginosa
(n = 97)
36 (37.9) 40 (42.1) 47 (49.5) 30 (31.6) 31 (32.6) 36 (38.5) 16 (16.8)
P. mirabilis
(n = 79)
29 (36.7) 44 (55.7) 20 (25.4) 9 (11.4) 4 (5.0) 19 (24.1) 1 (1.3)
AMG-R aminoglycoside-resistant, FQ-R fluoroquinolone-resistant, 3GC-R third-generation cephalosporin-resistant, P/T-R piperacillin/tazobactam-resistant, CARB-R
carbapenem-resistant, MDR multidrug-resistant, XDR extensively drug-resistant, E. coli, Escherichia coli; K. pneumoniae, Klebsiella pneumoniae; P. aeruginosa,
Pseudomonas aeruginosa; P. mirabilis, Proteus mirabilis
Table 4 Predictive model of multidrug-resistant gram-negative
bacteria in patients with complicated urinary tract infection: a
mixed-effects logistic regression model
Factors OR 95% CI p-Value
(Intercept) 0.1 0.06–0.16 < 0.001
Gender (male) 1.66 1.20–2.29 0.002
Acquisition in a medical facility 2.59 1.80–3.71 < 0.001
Indwelling urinary catheter 1.44 0.99–2.10 0.06
UTI within the previous year 1.89 1.28–2.79 0.001
Antibiotics within the previous 30 days 1.68 1.13–2.50 0.011
OR odds ratio, CI confidence interval, UTI urinary tract infection
Potential predictors included in the predictive model were age, sex, source of
infection, place of residency, functional capacity score, personal history of
myocardial infarction, congestive heart failure, peripheral vascular disease,
cerebrovascular disease, dementia, chronic pulmonary disease, ulcer disease,
diabetes mellitus, chronic kidney disease, hemiplaegia, solid tumor, liver
disease, metastatic tumor, Charlson score, infection acquisition site, presence
of indwelling urinary catheter, urinary retention, organ transplant, kidney
organ transplant, immunosuppressive therapy, active chemotherapy,
corticosteroid therapy, UTI within the previous year, previous 30-day antibiotic
treatment (including previous treatment with quinolones, penicillins,
cephalosporins, carbapenems, and other antibiotics), infection severity,
neurogenic bladder, obstructive uropathy, other urinary tract modification, and
chronic renal impairment
Fig. 2 Receiver operating characteristic curve of the predictive
model of multidrug-resistance in gram-negative bacteria. Figure 2
shows the evaluation of the discriminative power of the mixed-
effects logistic regression predictive model for multidrug-resistant
gram-negative bacteria among patients with complicated urinary
tract infection by the receiver operating characteristic curve using
observed multidrug-resistance incidence as the gold standard. AUC,
area under the curve; CI, confidence interval
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E. coli produced carbapenemases, mainly KPC-type and
OXA-48-like, in the countries represented in our study
[20]. However, 29% of K. pneumoniae isolates had un-
identified mechanisms of carbapenem resistance, and
almost 10% of K. pneumoniae isolates were resistant
to all antibiotics tested, consistent with our findings.
P. aeruginosa isolates showed a carbapenem-resistance
rate that reached 32%. In this case, the presence of a
Fig. 3 Observed versus predicted multidrug-resistant gram-negative bacteria risk, stratified by deciles of predicted risk (a) and by hospital (b).
a shows the observed to expected events by probability deciles and (b) shows the observed to expected events by hospital. Events are defined
as multidrug-resistant (MDR) gram-negative bacteria complicated urinary tract infections. Hospitals included in (b) are: 1. Soproni Erzsébet Oktató
Kórház és Rehabilitációs Intézet, 2. Hospital Universitari de Bellvitge, 3. Attikon University Hospital, 4. Hospital Universitario Virgen de la Macarena,
5. Hospital Universitario 12 de Octubre, 6. Infectious Diseases Hospital Sfanta Parascheva Iasi, 7. Tel Aviv Medical Center, 8. Rabin Medical Center
Campus Beilinson, 9. Cerrahpasa Medical School, 10. Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház, 11. Policlinico di
Modena, 12. AORN dei Colli – Monaldi, 13. National Institute for Infectious Diseases Matei Bals, 14. Rambam Health Care Campus, 15. University
Hospital Queen Joanna, 16. Kenezy Gyula Hospital, 17. National Institute for Infectious Diseases Lazzaro Spallanzani, 18. Ankara Numune Research
and Training Hospital, 19. Hippokration Hospital, 20. Emergency Hospital Pirogov
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urinary catheter was the most frequently associated factor.
Countries with the greatest rates of carbapenem-resistant
P. aeruginosa included Italy and Turkey, while those with
the lowest rates were Israel and Hungary. The mecha-
nisms of MDR in P. aeruginosa have been related to the
production of cephalosporinases, combined with muta-
tions that decrease carbapenem permeability of the bac-
terial cell wall [21–23]. The selective antibiotic pressure
caused by broad-spectrum antibiotics favours the emer-
gence of MDR strains, and once it is produced, its rever-
sion is very slow [24].
We have developed and internally validated a clinical
predictive model for hospitalised patients with suspected
cUTIs that helps determine the risk of MDR-GNB infec-
tions, considering the country’s baseline risk. This model
may be useful in reducing inappropriate empirical antibiotic
treatment that leads to poor clinical outcomes in these pa-
tients [25]. It may also help implement antibiotic steward-
ship programs that enhance the use of carbapenem-sparing
antibiotic regimens in patients at low risk for MDR
[24, 26]. The severity of infection based on physician’s
clinical judgement and severity scores needs to be assessed,
since non-severe cUTI will probably benefit more from
receiving treatment based on susceptibility testing [27].
Importantly, however, more severe cases with potentially
serious consequences of treatment failure could benefit
from applying our model.
The most reliable factor that predicted MDR was the
acquisition of cUTIs in medical care facilities, mostly
LTCFs. Most patients admitted to LTCFs are old, have
comorbidities, and are functionally dependent. These pa-
tients frequently receive repeated courses of antibiotics
for various reasons, including cUTIs. Thus, LTCFs have
been identified as important reservoirs of MDR-GNB
[28]. Besides patients having had a UTI within the previ-
ous year and having received antibiotics within the pre-
vious month, other predictive factors for MDR identified
by our model have been also described by other authors
[29, 30]. All of them reflect high cumulative exposure
to antibiotics and, consequently, selection of MDR en-
dogenous flora.
Male UTI is usually considered complicated due to the
more complex urinary tract anatomy. This implies lon-
ger antibiotic treatments and frequent relapse of infec-
tion, resulting in repeated antibiotic exposure and higher
risk of MDR [31].
The presence of a urinary catheter has been associated
with a higher risk of UTI [32, 33] and infections caused
by microorganisms with higher intrinsic resistance, such
as P. aeruginosa and Enterococcus spp. [1]. Our study
reaffirmed this observation since P. aeruginosa was
significantly associated with urinary catheter use. The
catheter inhibits the defence mechanisms of the urinary
tract epithelium against bacteria and facilitates the rapid
invasion of the bladder by microorganisms colonizing
the device. The urinary catheter also promotes the de-
velopment of bacterial biofilm, where antibiotics do not
achieve significant concentrations [34].
The main limitation of this study is that the model has
been validated in a group of hospitals from south and
eastern Europe, Turkey and Israel and the results may
not be generalizable to other populations. Therefore,
further external validation is necessary to confirm our
results. Also, the retrospective design and approach for
identifying cases could have led to underestimate
non-severe cases occurring in patients admitted due to
other reason than cUTI and who developed cUTI during
the hospitalisation. On the other hand, difficult to treat
MDR-GNB cUTIs could have been more easily identi-
fied. The main strength of the study is its large-scale,
multicenter, and multinational design including 948 pa-
tients and the case-validation system. Furthermore, the
effect of possible differences in MDR baseline risk by
each hospital on the main outcome was considered to
create the predictive model.
Conclusions
The current high rate of MDR-GNB infections among
hospitalised patients with cUTIs is alarming in south and
eastern Europe, Turkey and Israel. A high MDR rate has
been observed among K. pneumoniae and P. aeruginosa
isolates. Our study developed a predictive model that
could be useful in determining the risk for MDR-GNB
cUTI, with the purpose of targeting patients at high risk
with broad-spectrum antibiotics and guiding the imple-
mentation of antibiotic stewardship policies that enhance
the use of carbapenem-sparing antibiotic regimens in pa-
tients at low risk for MDR-GNB.
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